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Background: Alternative positron-emission tomography (PET) probes like labeled inhibitors of the prostate-specific
membrane antigen (PSMA) are of emerging clinical impact as they show the ability to image small lesions of recurrent
prostate cancer. Here, the dimerization of the pharmacophore Glu-ureido-Lys via the 68Ga chelator N,N′-bis[2-hydroxy-
5-(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) was investigated to further improve the binding
characteristics and pharmacokinetics.
Methods: The peptidomimetic structures were synthesized by solid-phase chemistry, and the resulting products were
coupled with the respective 2,3,5,6-tetrafluorophenol esters of HBED-CC to form the monomeric reference and the
dimeric Glu-ureido-Lys derivative. The binding properties were analyzed in competitive binding, internalization, and cell
surface retention experiments. PET images and biodistribution data were obtained 1 h after injection in BALB/c nu/nu
mice bearing LNCaP tumor xenografts.
Results: Cell binding data revealed significant better binding properties of the dimer (IC50 = 3.9 ± 1.8 nM; IC50
(monomer) = 12.1± 2.1 nM). The inhibition potency investigated by the enzyme-based NAALADase assay confirmed
these results. Specific internalization in LNCaP cells was demonstrated for both, the monomer and dimer. As shown by
efflux measurements, the dimeric compound was more effectively retained on the cell surface, resulting in advanced
in vivo properties (T/BMonomer = 9.2; T/BDimer = 26.5).
Conclusions: The dimeric [68Ga]7 is a promising imaging agent for PSMA-expressing tumors as it shows higher tumor
uptake while observing more favorable background clearance. As compared to the respective monomer, the higher
affinity and prolonged tumor retention additionally represent promising features and warrant further evaluation
regarding 68Ga-PET imaging of PSMA expression.
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The occurrence of metastases is one of the major causes of
morbidity and mortality in prostate cancer patients. The
early detection of these metastatic or recurrent lesions is
of high clinical relevance for staging, prognosis, and
therapy management [1,2]. In order to improve prostate
cancer imaging, a series of 11C- and 18 F-labeled choline
and acetate derivatives have been developed [3-7]. However,* Correspondence: m.eder@dkfz.de
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in any medium, provided the original work is pwith regard to the detection of small lesions of recurrent
prostate cancer, these radiopharmaceuticals were shown to
be limited in detecting lymph node metastases after radical
retropubic prostatectomy in patients with low PSA level
[8]. For example, [18 F]fluoroethylcholine positron-emission
tomography (PET)/CT only showed 71% sensitivity in the
detection of recurrent prostate cancer [9] which gave rise
to the development of alternative PET probes with more
specific targeting characteristics.
The prostate-specific membrane antigen (PSMA) repre-
sents a cell surface target suitable for imaging metastatic
lesions as it is expressed by nearly all prostate cancer cellsan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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metastatic, and hormone-refractory carcinomas [10,11].
Low levels of physiologic PSMA expression were detected
in the brain, kidney, spleen, liver, and small intestine [10],
whereas other human tissues showed no PSMA expression
at all [12-14]. PSMA-specific tracers can be considered as
ideal for imaging small lesions of recurrent or metastasized
prostate cancer since the PSMA expression even increases
with cancer progression [11]. Furthermore, they are
capable to visualize prostate cancer cells independent of
proliferation status [15-17].
Urea-based inhibitors of PSMA clear rapidly from the
circulation, leading to images with clear contrast
[18-23]. Further improvement of PSMA inhibitors
regarding affinity, specificity, and radiolabeling may lead
to significant clinical benefits as lesions could be
detected earlier and convenient kit-like radiolabeling
makes a tracer more accessible.
It has been previously reported that dimeric peptides
such as cyclic arginine-glycine-aspartic acid (RGD) exhibit
significant higher tumor uptake and prolonged retention
as compared to their corresponding monomeric analogues
[24-28]. Especially, the enhancement of tumor retention
results in higher contrast and opens the possibility of
using small molecules for therapy. In this context, we
synthesized a PSMA-selective dimer labeled with the 68Ga
complex of N,N′-bis[2-hydroxy-5-(carboxyethyl)benzyl]
ethylenediamine-N,N′-diacetic acid (HBED-CC) which
was recently proposed for efficient radiolabeling with 68Ga
at ambient temperature [29,30]. A convenient labeling
procedure combined with the usage of 68Ga might add-
itionally improve prostate cancer imaging. Furthermore,
the lipophilic 68Ga complex of HBED-CC proved to be fa-
vorable for the linker region, a feature which was found to
be necessary for a sustainable interaction with the PSMA
‘active binding site’ [21,31,32]. As a consequence, the
HBED-CC-labeled monomeric reference compound
showed promising preclinical results with high potential
for clinical translation [32,33]. Here, we present the syn-
thesis of the dimer, cell-based in vitro binding data, and
preliminary in vivo results.
Methods
All commercially available chemicals were of analytical
grade and were used without further purification. 68Ga
(half-life 68 min, β+ 89%, Eβ+ max. 1.9 MeV) was obtained
from a 68Ge/68Ga generator based on pyrogallol resin sup-
port [30,34]. Typically, 1 GBq 68Ga was eluted using
5.5 M HCl. The activity was trapped on a small anion-
exchanger cartridge (AG1X8, Biorad, Richmond, CA,
USA) as [68Ga]GaCl4
−. The radiogallium was eluted from
the cartridge in a final volume of 300 μL of ultrapure
water (Merck, Darmstadt, Germany) as [68Ga]GaCl3.
67Ga
was purchased from MDS Nordion (Fleurus, Belgium) as[67Ga]GaCl3 in 0.1 N HCl. Protected amino acids were
purchased from Novabiochem (Merck, Darmstadt,
Germany) or Sigma-Aldrich (Neu-Ulm, Germany).
The compounds were analyzed by reversed-phase
high-performance liquid chromatography (RP-HPLC;
Chromolith RP-18e, 100 × 4.6 mm; Merck, Darmstadt,
Germany). Analytical HPLC runs were performed using
a linear A-B gradient (0% B to 100% B in 6 min) at a
flow rate of 4 mL/min. Solvent A consisted of 0.1%
aqueous trifluoroacetic acid (TFA), and solvent B was
0.1% TFA in CH3CN or MeOH (in case of determin-
ation of radiochemical yield (RCY) or analysis of serum
stability).
The HPLC system (L6200 A; Merck-Hitachi, Darmstadt,
Germany) was equipped with a variable UV and a gamma
detector (Bioscan, Washington, DC, USA). UV absorbance
was measured at 214 and 254 nm. Mass spectrometry was
performed with a MALDI-MS Daltonics Microflex (Bruker
Daltonics, Bremen, Germany) system. ESI-MS analysis was
performed using an Orbitrap Mass Spectrometer (Exactive,
Thermo Fisher Scientific, Dreieich, Germany). Full-scan sin-
gle mass spectra were obtained by scanning from m/z=200
to 4,000.
Synthesis of protected Glu‐ureido‐Lys(Ahx) (5)
The binding motif was synthesized as previously described
[32]. Briefly, the synthesis started with the formation of the
isocyanate 2 (Figure 1) of the glutamyl moiety by using tri-
phosgene. A resin-immobilized (2-chloro-tritylresin, Merck,
Darmstadt, Germany), E-allyloxycarbonyl-protected lysine
was added and reacted for 16 h with gentle agitation result-
ing in compound 3. The resin was filtered off, and the
allyloxycarbonyl-protecting group was cleaved. The coup-
ling of the aminohexanoic linker was performed using fluor-
enylmethyloxycarbonyl (Fmoc)-protected 6-aminohexanoic
acid (Sigma-Aldrich, Germany). The product 4 was cleaved
from the resin with 30% 1,1,1,3,3,3-hexafluoroisopropanole
in CH2Cl2, resulting in the tert-butyl-protected product 5.
Purification was done using a Chromolith RP-18e column
(100×10 mm; Merck, Darmstadt, Germany) with a gradient
in 6 min starting at 0% B, raised to 60% B and followed by a
1-min increase to 100% B. Solvent A consisted of 0.1%
aqueous TFA, and solvent B was 0.1% TFA in CH3CN. The
flow rate was 6 mL/min.
The diastereomeric D-isomer (D-Glu-ureido-Lys(Ahx))
was synthesized using protected D-glutamate instead of L-
glutamate in the first step. The further synthesis and
purification was performed as described for the L-isomer.
Synthesis of the HBED-CC-conjugated monomer (6)
To conjugate HBED-CC, the purified product 5 was
reacted with 1.2 Eq of HBED-CC-2,3,5,6-tetrafluorophe-
nol (TFP) ester (synthesized as previously described [30])
in the presence of 2 Eq of N,N-diisopropylethylamine
Figure 1 Syntheses of Glu-ureido-Lys(Ahx)-HBED-CC (6) and [Glu-ureido-Lys(Ahx)]2-HBED-CC (7). (a) Triphosgene, DIPEA, CH2Cl2, 0°C; (b) H-Lys
(Alloc)-2CT-Resin, CH2Cl2; (c) Pd[P(C6H5)3]4, morpholine, CH2Cl2; (d) Fmoc-6-Ahx-OH, HBTU, DIPEA, DMF; (e) 20% piperidine, DMF; (f)
hexafluoroisopropanol/CH2Cl2; (g) HBED-CC-TFP ester, DIPEA, DMF; (h) TFA; (i) (HBED-CC)TFP2 diester, DIPEA, DMF; (j) TFA.
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purification (vide supra), the tert-butyl groups were
removed by TFA treatment at room temperature for 1 h,
resulting in the monomeric structure 6 (approximately
37% yield). Mass spectrometry was used to confirm the
identity of the compound (Table 1).
Syntheses of (HBED-CC)TFP2 and the HBED-CC-conjugated
dimer (7)
Active ester formations were performed in accordance









[Ga]6 947.4257 947.4250 3.1 9
[Ga]7 1,361.6387 1,361.6364 3.1 2
aHigh-resolution mass spectrometry data of the free ligands ([M+H]+); bcompounds
B to 100% B in 6 min) at a flow rate of 4 mL/min; solvent A was 0.1% aqueous TFAmonoactive ester [30]. To synthesize the bis-activated
ester (HBED-CC)TFP2, 1,000 μL of a 0.01 M [Fe(HBED-
CC)]− solution in DMF was supplemented with 10 Eq of
TFP and 4 Eq of N,N'-diisopropylcarbodiimide. After
3 days at room temperature, the product [Fe(HBED-
CC)]TFP2 was purified by preparative HPLC. After dilu-
tion with water, the iron complex of the bis-activated
ester was trapped on a preconditioned RP18 cartridge
(Waters SepPak-Classic C18; Waters Corporation,
Milford, MA, USA). To remove complexed Fe3+, the
cartridge was flushed with 3 mL of 1 M HCl and washedffinity-related IC50 determined
n enzyme-based assay (nM)c
Affinity-related IC50 determined
in cell-based assay (nM)c
.0 ± 1.1 12.1 ± 2.1
.1 ± 1.4 3.8 ± 1.8
were labeled with 68Ga; runs were performed using a linear A-B gradient (0%
, and solvent B was MeOH; ccompounds were complexed with natGa.
Schäfer et al. EJNMMI Research 2012, 2:23 Page 4 of 11
http://www.ejnmmires.com/content/2/1/23with 4 mL H2O. The remaining (HBED-CC)TFP2 ester
was eluted with 2 mL CH3CN and evaporated to dry-
ness. Based on a HPLC standard (known concentration
of (HBED-CC)TFP2, the isolated yield amounted to 40%
to 50%. MALDI-MS: m/z= 830.0 (calculated for [M+H]+
C32H33F4N2O10 829.7).
To form the dimer of Glu-ureido-Lys(Ahx), the bis-
activated (HBED-CC)TFP2 was reacted with 2.4 Eq of
the purified product 5 in the presence of 2.4 Eq of
DIPEA in DMF. After HPLC purification (vide supra),
the tert-butyl groups were cleaved at room temperature
for 1 h using TFA. Compound 7 was received with ap-
proximately 32% yield after HPLC purification. Mass
spectrometry confirmed the identity (Table 1).
68Ga labeling
Glu-ureido-Lys(Ahx)-HBED-CC (6, 0.1 to 1 nmol in
0.1 M 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer, pH=7.5, 100 μL) or [Glu-ureido-Lys
(Ahx)]2-HBED-CC (7, 0.1 to 1 nmol in 0.1 M HEPES buf-
fer, pH=7.5, 100 μL) was added to a mixture of 10 μL of
HEPES solution (2.1 M) and 20 μL of [68Ga]Ga3+ eluate
(50 to 100 MBq). The pH of the labeling solution was
adjusted to 4.2 using 30% NaOH. The reaction mixture
was incubated at room temperature for 2 min. The RCY
was determined via analytical RP-HPLC.
67Ga labeling
Typically, 0.1 nmol of 6 or 7 (in 0.1 M HEPES buffer,
pH= 7.5, 100 μL) was added to 10 μL of HEPES solution
(2.1 M), 2 μL of 1 N HCl, and 10 μL of [67Ga]GaCl3 (ap-
proximately 100 MBq) in 0.1 N HCl, resulting in a solu-
tion with a pH of 4.2. The reaction mixture was
incubated for 2 min at ambient temperature. The RCY
was determined via RP-HPLC.
natGa complexes
A 10-fold molar excess of Ga(III)-nitrate (Sigma-
Aldrich) in 0.1 N HCl (10 μL) was reacted with com-
pounds 6 or 7 (1 mM in 0.1 M HEPES buffer, pH= 7.5,
40 μL) in a mixture of 10 μL of HEPES solution (2.1 M)
and 2 μL of 1 N HCl for 2 min at 80°C. The pH of the
labeling solution was 4.2.
Radiochemical stability
The radiochemical stability was analyzed in both
phosphate-buffered saline (PBS) and human serum. After
2 h of incubation at 37°C, an equal volume of CH3CN was
added to the samples to precipitate serum proteins. Subse-
quently, the samples were centrifuged for 5 min at
13,000 rpm. Aliquots of the supernatant and the PBS
sample were analyzed via RP-HPLC. In addition, serum
samples were run on a Superdex 75 GL 5/150 gel filtrationcolumn (GE Healthcare, Munich, Germany) to analyze
potential protein binding (PBS pH 7 as eluent).
To analyze the complex stability against human
transferrin, a 400-μL aliquot was added to 250 μg of
apo-transferrin in PBS at pH 7 and incubated at 37°C
(water bath) for 2 h. The complex stability was deter-
mined using a Superdex 75 GL 5/150 short column with
PBS pH 7 as eluent.
NAALADase assay
Recombinant human PSMA (rhPSMA, R&D Systems,
Wiesbaden, Germany) was diluted in an assay buffer
(50 mM HEPES, 0.1 M NaCl, pH= 7.5) to 0.4 μg/mL.
The substrate Ac-Asp-Glu (Sigma, Taufkirchen,
Germany; 40 μM final concentration) was mixed with
[natGa]6 or [natGa]7 at concentrations ranging from 0.05
to 1,000 nM in a final volume of 125 μL of assay buffer.
The mixtures were combined with 125 μL of the
rhPSMA solution (0.4 μg/mL) and incubated for 1 h at
37°C. The reaction was stopped by heating at 95°C for
5 min. A 15-mM solution of ortho-phthaldialdehyde
(250 μL) was added to all vials and incubated for 10 min
at ambient temperature. Finally, 200 μL of the reaction
solutions was loaded onto an F16 Black Maxisorp Plate
(Nunc, Langenselbold, Germany) and read at excitation
and emission wavelengths of 330 and 450 nm, respect-
ively, using a microplate reader (DTX-880, Beckman
Coulter, Krefeld, Germany). The data were analyzed
using a one-site total binding regression algorithm of
GraphPadPrism (GraphPad Software, San Diego, CA,
USA).
Cell culture
For binding studies and in vivo experiments, PSMA+
LNCaP cells (metastatic lesion of human prostatic adeno-
carcinoma, ATCC CRL-1740) and PSMA− PC-3 cells
(bone metastasis of a grade IV prostatic adenocarcinoma,
ATCC CRL-1435) were cultured in DMEM medium sup-
plemented with 10% fetal calf serum and 2 mmol/LL-glu-
tamine (all from Invitrogen, Carlsbad, CA, USA). During
cell culture, cells were grown at 37°C in an incubator with
humidified air, equilibrated with 5% CO2. The cells were
harvested using trypsin-ethylenediaminetetraacetic acid
(trypsin-EDTA; 0.25% trypsin, 0.02% EDTA, all from Invi-
trogen) and washed with PBS.
Cell binding and internalization
In order to determine the binding affinity, a competitive
cell binding assay was performed. LNCaP cells (105/well)
were incubated with a 0.2-nM solution of [67Ga]6 in the
presence of 12 different concentrations of [natGa]6 or
[natGa]7 (0 to 5,000 nM, 200 μL/well). After incubation
at ambient temperature for 1 h with gentle agitation, the
binding buffer was removed using a multiscreen vacuum
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twice with 100 μL and once with 200 μL of ice-cold
binding buffer, the cell-bound radioactivity was mea-
sured using a gamma counter (Packard Cobra II, GMI,
Ramsey, MN, USA). The 50% inhibitory concentration
(IC50) values were calculated by fitting the data using a
nonlinear regression algorithm (GraphPad Software).
Experiments were performed three times.
Internalization experiments were performed as previously
described [35]. Briefly, 105 LNCaP or PC-3 cells were seeded
in poly-L-lysine-coated 24-well cell culture plates 24 h be-
fore incubation. After washing with PBS, the cells were
incubated with the radiolabeled compounds [68Ga]6 or
[68Ga]7 (25 nM final concentration) for 45 min at 37°C and
at 4°C, respectively. To determine specific cellular uptake,
cells were blocked with 2-(phosphonomethyl)-pentanedioic
acid (PMPA, Axxora, Loerrach, Germany) to a final concen-
tration of 100 μM. Cellular uptake was terminated by wash-
ing four times with 1 mL of ice-cold PBS. To remove
surface-bound radioactivity, cells were incubated twice with
0.5 mL glycine-HCl in PBS (50 mM, pH=2.8) for 5 min.
The cells were washed with 1 mL of ice-cold PBS and lysed
using 0.3 N NaOH (0.5 mL). The surface-bound and the
internalized fractions were measured in a gamma counter.
Cell surface retention
The determination of cell surface retention was per-
formed in accordance to a previously described experi-
ment [36]. Briefly, 5 × 106 LNCaP cells in a 320-μL
RPMI 1640 medium were incubated with [68Ga]6 or
[68Ga]7 (25 nM final concentration), respectively, for
45 min at 37°C. Cells were washed three times and
resuspended in the RPMI 1640 medium (320 μL); sam-
ples were taken as a control for total cell-associated
activity (cell surface bound and internalized). Subse-
quently, 0.5 μL of a 2-PMPA solution (100 mmol/L in
DMSO) was added to avoid rebinding and to enhance
the competitive pressure on releasing the radioactivity
from the cell surface. At indicated time points, 10-μL
samples were taken and transferred on top of a 400-μL
microcentrifuge tube containing 350 μL of a 75:25 mix-
ture of silicon oil (density 1.05; Aldrich), and mineral oil
(density 0.872; Acros, Thermo Fisher Scientific) [37].
Subsequently, the tubes were centrifuged at 12,000 rpm
for 2 min to separate cellular radioactivity and radio-
activity solved in the medium. After freezing in liquid ni-
trogen, the bottom tips containing the cell pellet were
cut off. The cell pellets and the medium were measured
in a gamma counter to determine cellular uptake
Biodistribution and PET imaging%uptake ¼ 100 cpm in pellet
cpm in pelletþ cpm in supernatant
 Male BALB/c nu/nu mice of 7 to 8 weeks old (Charles
River Laboratories, Wilmington, MA, USA) were sub-
cutaneously inoculated into the right trunk with 5 × 106
cells of either LNCaP or PC-3 (both in 50% Matrigel;
Becton Dickinson, Heidelberg, Germany). The tumors
were allowed to grow for 3 to 4 weeks until approxi-
mately 1 cm3 in size. The 68Ga-radiolabeled compounds
were injected into a tail vein (1 to 2 MBq/mouse; 0.1 to
0.2 nmol). At 1 h after injection, the animals were sacri-
ficed. Organs of interest were dissected, blotted dry, and
weighed. The radioactivity was measured using a gamma
counter and calculated as percentage injected dose per
gram (% ID/g).
For the microPET studies, 10 to 25 MBq of either
[68Ga]6 or [68Ga]7 in a volume of 0.15 mL (approxi-
mately 0.5 nmol) was injected via a lateral tail vein into
mice bearing LNCaP tumor xenografts. The anesthetized
animals (2% sevoflurane, Abbott, Wiesbaden, Germany)
were placed in prone position into an Inveon small
animal PET scanner (Siemens, Knoxville, TN, USA) to
perform a 50-min dynamic microPET scan starting at
1 min post-injection followed by a 20-min static scan.
All animal experiments complied with the current laws
of the Federal Republic of Germany.
Statistical aspects
All experiments were performed at least in triplicate.
Quantitative data were expressed as mean ± standard de-
viation (SD). If applicable, means were compared using
Student's t test. P values <0.05 were considered statisti-
cally significant.
Results
Synthesis of the monomeric and dimeric PSMA inhibitors
The synthesis of intermediate 5, which exposes an un-
protected amino group for further coupling of the
HBED-CC active esters, was carried out by solid-phase
chemistry (Figure 1). The monomeric reference 6, previ-
ously described and characterized [32], was formed by
reacting the monoactive ester of HBED-CC with the
protected binding motif 5. The dimer 7 was obtained
from a reaction of bis-activated HBED-CC-TFP ester
with 5. Analytical data of the HBED-CC conjugates 6
and 7 are summarized in Table 1.
Radiolabeling and stability
Low precursor amounts and low concentrations of com-
pounds 6 or 7 (0.1 nmol; 1.7 μM) were sufficient to gain
RCYs of >99% after a 2-min reaction time at room
temperature. Specific activities of >500 GBq/μmol could
be obtained for both formats. As a consequence of high
RCY, the biological testing was performed without fur-
ther purification of the radioligands. The analytical data
are summarized in Table 1.
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was investigated in human serum for 2 h at 37°C and in
PBS in the presence of 10 μM transferrin. Both assays
proved the stability of the compounds with respect to hy-
drolysis and trans-complexation. After 2 h of incubation,
HPLC analysis revealed 99% intact [68Ga]6 and [68Ga]7.
Furthermore, no changes in size exclusion chromatog-
raphy were detected after incubation in human serum or
in the presence of apo-transferrin.
Determination of PSMA affinity
In order to determine the binding affinity, the variants
were competitively analyzed in an enzyme-based assay
on rhPSMA (NAALADase assay) and in a cell binding
assay with LNCaP cells using 67Ga-labeled 6 (radiochem-
ical purity> 99%, specific activity approximately
1,000 GBq/μmol) as radioligand. The affinity-related
IC50 values of both assays indicated an improved affinity
of at least a factor of 3 of the dimeric compound [natGa]
7 as compared to the monomer [natGa]6 (P< 0.05). The
IC50 values are summarized in Table 1.
Internalization and efflux
Internalization experiments on LNCaP and PC-3 cells
indicated specific cell surface binding and internalization
of [68Ga]6 and [68Ga]7 (Figure 2a). The uptake in PSMA+
LNCaP cells was blocked in the presence of 2-PMPA, and
both compounds showed no binding to PSMA− PC-3
cells at all. The dimeric compound [68Ga]7 significantly
showed higher cellular uptake (40.04 ± 6.09% (dimer),
23.24± 2.17% (monomer); P=0.01), while both substances
were internalized to approximately 25%. This results in a
higher absolute amount of internalized radioactivity using
the dimer. The efflux experiment showed prolonged cell
surface retention of the dimeric compound (Figure 2b),
while the lower plateau of both dissociation curves seems
to represent the internalized fraction of the compounds,
indicating that only surface-bound radioactivity is released
from the cells. As shown in Figure 2b, the monomer
reached the internalized level earlier, resulting in higher
overall cellular uptake of the dimer at all time points
(Figure 2c).
Biodistribution and PET imaging
The biodistribution data are summarized in Table 2 and
Figure 3a. Both, the monomeric compound [68Ga]6 and
the dimeric compound [68Ga]7, were cleared rapidly
from the circulation and PSMA− tissues. In comparison
to the monomer [68Ga]6, the dimeric compound [68Ga]7
showed no higher uptake in PSMA− organs like the lung
or intestine at 1 h post-injection. The liver uptake of
both compounds was low (1.43 ± 0.19% ID/g ([68Ga]6),
1.29 ± 0.11% ID/g ([68Ga]7)).The kidney uptake of 139.44± 21.40% ID/g ([68Ga]6)
and 133.43± 18.88% ID/g ([68Ga]7) could be blocked after
the co-injection of 2 mg/kg of PMPA to 4.02± 1.14% ID/g
([68Ga]6) and 8.29± 0.83% ID/g ([68Ga]7), respectively
(Figure 3b). The spleen uptake was similarly reduced after
blocking, 17.90± 2.87% ID/g ([68Ga]6) and 17.88 ± 4.53%
ID/g ([68Ga]7) vs. 1.54± 0.33% ID/g ([68Ga]6) and
0.67± 0.11% ID/g ([68Ga]7), respectively. The tumor up-
take was 8.22 ± 1.78% ID/g for the dimer and
4.89 ± 1.34% ID/g for the monomer 1 h p.i. (P= 0.02).
Remarkably, the dimer shows a significant lower uptake
in the blood (P= 0.002) and a trend to lower background
activity (Table 2). Together with the faster blood clear-
ance, the improved tumor uptake of the dimer resulted
in a considerable higher tumor-to-blood ratio of 26.5
(T/Bmonomer = 9.2).
The microPET coronal slices of tumor-bearing mice
shown in Figure 4a,b indicate the enhanced tumor up-
take of [68Ga]7. The microPET time-activity curves
(Figure 4c) clearly demonstrate improved tumor reten-
tion of the dimer while observing comparable muscle
washout of both compounds. The time-activity curves in
Figure 4d show rapid elimination of radioactivity from
important organs, proving the early formation of high
tumor-to-background contrast.
The PSMA specificity of both tracers was confirmed by
investigating the organ distribution with PSMA− PC-3
tumor-bearing mice. The tumor uptake values amounted
to 1.30± 0.12% ID/g ([68Ga]6) and 0.93± 0.53% ID/g
([68Ga]7) (Figure 3a). Additional demonstration of the
in vivo specificity of the dimeric PSMA inhibitor [68Ga]7
was obtained by the comparison with the respective D-
isomer [68Ga]D-7 (Figure 5). [68Ga]D-7 shows consider-
ably reduced binding capacity to PSMA-expressing
LNCaP cells as compared to the L-form [68Ga]7
confirmed by competitive cell binding experiments (Ki(D-
7)> 5 μM). As a consequence, the L-isomer showed
accumulation in the tumor, whereas the D-isomer is
cleared as rapidly as from the muscle.
Discussion
PET imaging with [18 F]FDG, radiolabeled choline, and
acetate is hampered by the generally low glycolytic rate and
slow growth of most prostate tumors [38,39]. Tracers bind-
ing to overexpressed cell surface receptors such as PSMA
are more favorable since they bind prostate cancer cells in-
dependent of proliferation [15-17]. Furthermore, PSMA
exhibits the potential to be effectively internalized via
clathrin-coated pits and subsequent endocytosis [40] which
leads to enhanced tumor cell retention of the radiotracer
and, accordingly, to a better image quality.
Here, we describe the dimerization of Glu-ureido-Lys, the
PSMA-targeting pharmacophore, using the heterobifunc-




































































































Figure 2 Cell binding and internalization of [68 Ga]6 and [68 Ga]7 (A). Specific cellular uptake was evaluated by blockage using 100 μM 2-
PMPA. (B) The graph shows the release of radioactivity from cells in percentage of initially bound compound. (C) The release of radioactivity
related to the initial cellular uptake derived from A. Values in A and C are expressed as percentage of applied radioactivity bound to 106 cells.
Data are expressed as mean± SD (n= 3).
Table 2 Organ distribution (1 h post-injection) of [68Ga]6
and [68Ga]7 in BALB/c nu/nu mice
Organ Monomer [68Ga]6 Dimer [68Ga]7
Blood 0.53 ± 0.04 0.31 ± 0.03
Heart 0.83 ± 0.08 0.90 ± 0.12
Lung 2.36 ± 0.27 2.25 ± 0.24
Spleen 17.90 ± 2.87 17.88 ± 4.53
Liver 1.43 ± 0.19 1.29 ± 0.11
Kidney 139.44 ± 21.40 133.43 ± 18.88
Muscle 1.00 ± 0.24 0.90 ± 0.01
Intestine 1.14 ± 0.46 0.57 ± 0.14
Brain 0.40 ± 0.19 0.17 ± 0.01
PC-3 tumor 1.30 ± 0.12 0.93 ± 0.53
LNCaP tumor (n= 5) 4.89 ± 1.34 8.22 ± 1.78
Injection dose was 1 to 2 MBq/mouse, 0.1 to 0.2 nmol. Data are expressed as
% ID/g ± SD, n= 3.
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chains of PSMA, one oxygen being part of the zinc complex
in the active center, and as provided by HBED-CC, an aro-
matic structure element which is able to interact with the
hydrophobic part of the enzyme composed of tyrosines
[31,32]. Molecules lacking one of these interactions showed
other modes of action resulting in weaker binding or dra-
matically reduced internalization rates [31]. As a conse-
quence, both the determination of affinity and the
internalization rate are crucial for the characterization of
PSMA inhibitors. Considering the particular characteristics
of the PSMA binding pocket [31], especially, the
internalization rate might be influenced by two hydrophilic
pharmacophores on both sides of the HBED-CC scaffold.
Since the affinity was significantly enhanced and the
internalization rate has not been negatively affected, the
BA

































































Figure 3 Organ distribution expressed as % ID/g tissue 1 h post-injection. (A) Comparison of the monomer [68Ga]6 and the dimer [68Ga]7.
(B) PSMA blocking by co-administration of 2 mg of 2-PMPA/kg body weight. Data are expressed as mean± SD (n= 5).
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http://www.ejnmmires.com/content/2/1/23dimer shows an improved interaction with the active bind-
ing site. As the chelator is simultaneously used as
dimerization scaffold, complexing moiety, and lipophilic






































Figure 4 Whole-body coronal microPET image of an athymic male nu
and the dimer [68Ga]7 (B) were evaluated by a dynamic microPET scan foll
and [68Ga]7 are shown in (A) and (B), respectively. Approximately 15 MBq/m
curves in the muscle and tumor for both tracers. (D) The graph demonstraPSMA inhibitor with exceptionally low molecular size. This
is considered as an important issue since the size of a radio-
pharmaceutical tracer is often crucial in terms of pharma-
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ouse was injected. (C) The graph shows the respective time-activity
tes the elimination of [68Ga]7 from other organs in PET.

















Figure 5 Time-activity curves of [68Ga]7 and [68Ga]D-7 taken from dynamic PET measurements and expressed as % ID/g.
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http://www.ejnmmires.com/content/2/1/23Dimerization is a suitable methodology to enhance the
binding properties of tumor-targeting tracers. For ex-
ample, cyclic RGD dimers, such as E[c(RGDfK)]2, were
developed as diagnostic and therapeutic radiotracers with
improved binding and imaging properties [27,41]. How-
ever, the improvement of binding capacity by dimerization
is often accompanied by higher kidney or liver uptake of
the tracer [27]. Thus, dimerization can unfavorably influ-
ence pharmacokinetics or targeting properties, resulting in
less advantageous tumor-to-background ratios [42,43].
Our results did not indicate unfavorable influences on
pharmacokinetics as a consequence of dimerization. The
PSMA-specific HBED-CC dimer [68Ga]7 is cleared even
faster than the respective monomer [68Ga]6 and showed
nearly no unspecific liver uptake. A blocking experiment
showed that the initial high kidney uptake was mainly
PSMA specific. The improved background clearance of
the dimer and the enhanced tumor uptake (a factor of ap-
proximately 1.7) resulted in a considerably improved
tumor-to-blood ratio (T/Bdimer = 26.5; T/Bmonomer = 9.2) at
1 h post-injection.
In order to characterize in vitro properties, the affinity,
cellular uptake, and cell surface retention of the molecules
were studied. The affinity constants determined on both,
the purified receptor and LNCaP cells, indicated signifi-
cantly higher affinity of the dimer. Since higher affinity of
dimeric compounds is often caused by reduced dissoci-
ation rates, the cell surface retention of both compounds
has been studied in a cell surface retention experiment.
To avoid rebinding of released radioactivity, 2-PMPA was
added as a competitor during the experiment. As a conse-
quence, it was possible to detect the internalized fraction
level (Figure 2b) beyond which the gallium complexes are
no longer released. The released radioactivity is, therefore,
only related to the cell surface-bound activity.
The prolonged cell surface retention of the dimer is in
agreement with the higher affinity of [68Ga]7, indicating
that the dissociation rate was improved by dimerization.
The higher amount of cell surface-bound radioactivityand the prolonged contact with the cell surface resulted
in a higher absolute amount of internalized radioactivity.
The excellent PSMA specificity of the probes found in
cell binding assays was demonstrated in vivo by compar-
ing the organ distribution data using PSMA+ (LNCaP)
and PSMA− (PC-3) tumor xenografts. Additional proof
of specificity was obtained with a dimer containing D-
Glu. The time-activity curves obtained from dynamic
PET measurements of this nearly non-binding isomer
[68Ga]D-7 demonstrated the large difference in tumor
uptake (Figure 5).
Another proof of specificity of the PSMA-binding
68Ga complexes was obtained through the blockade of
the high kidney and spleen uptake values with co-
injected 2-PMPA (Figure 3b), indicating that the uptake
was mainly mediated by specific binding to physiologic-
ally expressed PSMA in those murine organs [44-47].
A limitation of this study seems to be the high kidney
uptake of the investigated monomer and dimer. There
are numerous examples of variably labeled urea-based
molecules with extremely high murine kidney uptake
[18,19,23,48,49]. It was shown in these and in our stud-
ies that the uptake is mainly specific as a consequence of
physiologically expressed PSMA in murine kidneys
[18,32]. With regard to clinical translation, however, it
should be mentioned that PSMA expression is lower in
human kidneys [50], leading to encouraging clinical
results with those tracers [33].
Conclusions
Taken together, it could be demonstrated that the [68Ga]7
complex shows an improved PSMA affinity, higher cell
uptake, and prolonged cell surface retention as compared
to the monomeric [68Ga]6. The enhanced tumor uptake
and retention together with the faster washout from back-
ground organs resulted in a higher tumor-to-background
ratio. These promising features favor the application of
the dimer for PET imaging with the short-lived 68Ga. The
convenient labeling technology might influence the
Schäfer et al. EJNMMI Research 2012, 2:23 Page 10 of 11
http://www.ejnmmires.com/content/2/1/23introduction into clinical routine, helping to improve the
diagnosis of recurrent prostate cancer.
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